Jun 2026 (Q2 FY26) — Aug 12, 2026
Ituran Q2 FY26 — Record Revenue and Profitability Driven by Strong Subscriber Growth
Read the full callIturan earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Price
1Y: $37.05 on 17 Oct 2025 → $50.25. High $66.37 (2 Jun 2026), low $36.06 (19 Nov 2025).
Overview
Call summaries
Ituran Q2 FY26 — Record Revenue and Profitability Driven by Strong Subscriber Growth
Read the full callEvery analysed call
Financials
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | 130 | 116 | 128 | 143 | 169 | 204 | 226 | 244 |
| Total liabilities | 214 | 203 | 183 | 155 | 138 | 138 | 136 | 162 |
| Fixed assets | 50 | 46 | 38 | 36 | 46 | 42 | 33 | 39 |
| Investments | 2 | 0 | 7 | 4 | 0 | 0 | 0 | 0 |
| Total assets | 374 | 339 | 312 | 293 | 291 | 319 | 327 | 386 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 53 | 60 | 60 | 56 | 45 | 77 | 74 | 89 |
| Cash from investing | -85 | -18 | -11 | -19 | -27 | -17 | -16 | -24 |
| Cash from financing | 50 | -39 | -29 | -59 | -36 | -33 | -32 | -43 |
| Net cash flow | 14 | 3 | 18 | -22 | -22 | 26 | 24 | 30 |
| Capital expenditure | -22 | -18 | -10 | -17 | -27 | -14 | -14 | -22 |
| Free cash flow | 32 | 41 | 50 | 39 | 19 | 63 | 61 | 67 |
No filings in the last 12 months.
No officer, director or 10% owner of ITRN filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Ituran Location & Control Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading